Navigation Links
ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
Date:4/23/2009

s retains worldwide rights to ANA598, which was fully discovered at the Company. Preclinical evaluation of ANA598 was completed in the first quarter of 2008, leading to submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA), subsequent allowance of the IND by the FDA and initiation of clinical investigation in the second quarter of 2008. In December 2008, Anadys announced that the FDA granted fast track designation to ANA598 for the treatment of chronic HCV.

In October 2008, Anadys initiated patient dosing in the Phase Ib study of ANA598 in HCV patients and in February 2009 Anadys initiated dosing in a 14 day study in healthy volunteers.

In an earlier Phase I study in healthy volunteers, ANA598 was administered as capsules at single oral doses of 400 mg, 800 mg, 1400 mg, 2000 mg (fed and fasted) and 3000 mg. In addition, a separate cohort received two 800 mg doses 12 hours apart. ANA598 was well tolerated at all doses and there were no serious adverse events or withdrawals from the study. All reported adverse events were classified as mild or moderate, with no apparent dose relationship. The pharmacokinetic profile demonstrated sustained plasma levels of ANA598 consistent with the potential for once-daily or twice-daily oral dosing.

In the preclinical program, ANA598 was well tolerated at all doses tested in 28-day GLP toxicology studies. In September 2008, Anadys initiated long-term, chronic toxicology studies of ANA598.

If ANA598 is successful in early stage development, the Company anticipates completion of the clinical, toxicology and manufacturing activities required to initiate Phase II studies of ANA598 in combination with current standard of care in mid-2009.

Clinical Need and Market Opportunity in HCV Infection

Chronic HCV infection is a serious public health concern affecting ap
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
2. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
3. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
9. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
10. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
11. Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Kan. , July 25, 2014 /PRNewswire-iReach/ -- ... and TCGRx, of Powers Lake, Wisconsin ... partners in a distribution and co-marketing agreement allowing ... retail pharmacies throughout the United States ... robotics-based pharmacy management and workflow systems to retail ...
(Date:7/25/2014)... , July 25, 2014 Cardinal Health will ... pharmacies as winners of its prestigious Independent Pharmacy Best ... , one of the nation,s largest gatherings of independent ... – family-owned pharmacies from Ohio , ... – were selected for implementing exceptionally creative ...
(Date:7/25/2014)... DUBLIN , July 25, 2014 ... the "Global Ophthalmic Diagnostic Devices Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 About Ophthalmic Diagnostic Device ... device used to identify a defect or deficiency in ... patients with ophthalmic disorders such as presbyopia, cataracts, glaucoma, ...
Breaking Medicine Technology:ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 3Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 2Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 3Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 4Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 5Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 6Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2
... presented at NACFC and ICAAC/IDSA meetings this week, ... Inc. today,announced additional clinical and preclinical results with ... delivered by,an Investigational eFlow Nebulizer System for use ... (COPD). Clinical results show,that aerosol dosing of MP-376 ...
... 23 , - First Responses in Solid ... role in cell duplication and are,implicated in both ... tumour. A,lecture focusing on Aurora kinase inhibitors will ... 20th EORTC-NCI-AACR Symposium "Molecular,Targets and Cancer Therapeutics" organised ...
Cached Medicine Technology:Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis 2Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis 3Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis 4Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis 5Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis 6Nerviano Medical Sciences Invited by EORTC-NCI-AACR to Present the State-of-the-Art of Aurora 2Nerviano Medical Sciences Invited by EORTC-NCI-AACR to Present the State-of-the-Art of Aurora 3
(Date:7/26/2014)... (PRWEB) July 26, 2014 According to ... Vkool.com, this is a comprehensive bodybuilding program that helps ... using anabolic steroids . The program also instructs ... without cardio. , Vkool reveals in its review ... workouts that can help men get ripped and jacked ...
(Date:7/26/2014)... The birth control safety center at ... of new legal information on the site. A federal ... of lawsuits pending for July alleging side effects from ... those using popular prescription drugs and medical devices. By ... legal news all in one place, they can see ...
(Date:7/25/2014)... Dallas, TX (PRWEB) July 26, 2014 ... China Laser Scanning Confocal Microscope Industry” is ... China Laser Scanning Confocal Microscope market. The ... information, including Laser Scanning Confocal Microscope definition, ... as industry overview. This research covers international market ...
(Date:7/25/2014)... New York, New York (PRWEB) July 25, 2014 ... for dismissal and summary judgment in two DePuy Pinnacle ... cases, paving the way for the claims to go ... LLP reports. In an opinion rendered on July 18th, ... of Texas, ruled that the two Plaintiffs’ claims may ...
(Date:7/25/2014)... July 25, 2014 Consuming too much ... to know? , Read the labels! , Learn to ... how it relates to health during a "Healthy Eating ... 1 at Humility House, 755 Ohltown Road, Austintown. , ... an informational discussion and answer questions. , The ...
Breaking Medicine News(10 mins):Health News:Metabolic Enhancement Training Review Exposes Scott Abel's Program for Bodybuilding – Vkool.com 2Health News:Metabolic Enhancement Training Review Exposes Scott Abel's Program for Bodybuilding – Vkool.com 3Health News:DrugNews Adds Latest Court Updates on Mirena IUD Lawsuits 2Health News:Laser Scanning Confocal Microscope Market: 2014 Global, China Manufacturing Bases Analysis Now at DeepResearchReports.com 2Health News:Laser Scanning Confocal Microscope Market: 2014 Global, China Manufacturing Bases Analysis Now at DeepResearchReports.com 3Health News:Laser Scanning Confocal Microscope Market: 2014 Global, China Manufacturing Bases Analysis Now at DeepResearchReports.com 4Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 2Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 4Health News:Learn to Decipher Food Labels at Humility House 2
... , Achievements in Research, Education and Advocacy Cause for Celebration ... 2009 will be remembered as a year of many firsts for ... potential new treatment for lupus, the launch of the first-ever Ad ... on the barriers to lupus drug development. And it appears ...
... Washington, D.C. -- A new study in the journal ... drug-resistant strains of Acinetobacter, a dangerous type of bacteria ... study is being posted online today and will appear ... patients in hospital intensive care units (ICUs) and others ...
... on hundreds of other genes that help disease spread ... in concert seem to spur the deadliest form of brain ... life last August. , Scientists reporting in the Dec. 23 ... duo of genes are turned on in about 60 percent ...
... available in German . , Many brain training ... products even claim that brain training can prevent dementia in old ... brain exercises can have this effect. That is what the German ... in information published on informedhealthonline.org today. ...
... , WATERTOWN, Mass., Dec. 23 To strengthen ... season, Exergen® Corporation has introduced sponsorship of "game-time temperature" ... upcoming College Bowl football games. , The "Exergen Game-Time ... the thermometry industry and is currently running on Sunday ...
... Visiting Physicians Association, which is based in Farmington ... state of Michigan $9.5 million to settle allegations that ... false claims to Medicare, TRICARE and the Michigan Medicaid ... Association is a Michigan professional corporation which has provided ...
Cached Medicine News:Health News:2009: A Year of Many Firsts in Efforts to Overcome Lupus 2Health News:2009: A Year of Many Firsts in Efforts to Overcome Lupus 3Health News:2009: A Year of Many Firsts in Efforts to Overcome Lupus 4Health News:2009: A Year of Many Firsts in Efforts to Overcome Lupus 5Health News:2009: A Year of Many Firsts in Efforts to Overcome Lupus 6Health News:New study shows rise in drug resistance of dangerous infection in US hospitals 2Health News:Two Genes Work in Tandem to Spur Deadliest Brain Cancer 2Health News:Brain training can help improve specific abilities in older people 2Health News:Exergen TemporalScanner Sponsors 'Game Time Temperature' for NFL and College Bowl Games 2Health News:Visiting Physicians Association to Pay $9.5 Million to Resolve False Claims Act Allegations 2
... the art software package designed to assist in ... by a lens manufacturer with years of experience ... is designed to help you run your lab ... the software dictates., ,Designed specifically for integrated retail ...
... The table-mounted knee retractor ... for total knee arthroplasty ... open-frame design allows for ... knee during the procedure. ...
... for every general surgery need. No matter ... the GO550/GO500 Omni-Flex General Retractor Systems give ... simplest way possible., ,With large and small ... arm, the GO550 provides comprehensive flexibility and ...
... sounds you need to hear! ... body sounds while reducing distracting ... Model 3000., ,With Ambient Noise ... 18 times amplification, and a ...
Medicine Products: